Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BY 101298

Next Previous
Drug Profile

BY 101298

Alternative Names: AMO-959; BY-101298; BY-1298

Latest Information Update: 19 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chengdu Baiyu Pharmaceutical
  • Class Antineoplastics; Small molecules
  • Mechanism of Action DNA-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Prostate cancer; Solid tumours

Most Recent Events

  • 16 Dec 2025 Phase-I/II clinical trials in Prostate cancer (Combination therapy, Hormone refractory, Metastatic disease, Second-line therapy or greater) in Australia (unspecified route) (NCT07226986)
  • 12 Nov 2025 Novartis Pharmaceuticals plans a phase Ib/II trial for Prostate cancer (Combination therapy, Hormone refractory, Metastatic disease, Second-line therapy or greater) in December 2025 (PO) (NCT07226986)
  • 18 Oct 2024 Chengdu Baiyu Pharmaceutical terminates a phase Ib/II trial in Solid tumours (Late-stage disease, Second-line therapy or greater) in China due to the sponsor adjusts the clinical development strategy (PO) (NCT06524804)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top